HCM Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HCM from our risk checks.
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.93 |
| 52 Week High | UK£3.53 |
| 52 Week Low | UK£1.74 |
| Beta | 0.65 |
| 1 Month Change | -13.82% |
| 3 Month Change | 3.53% |
| 1 Year Change | 33.79% |
| 3 Year Change | -29.99% |
| 5 Year Change | -36.17% |
| Change since IPO | 1,069.66% |
Recent News & Updates
Recent updates
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease
Apr 04
HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce
Mar 14The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts
Mar 01Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues
Dec 18HUTCHMED (China) (LON:HCM) Is Using Debt Safely
Nov 23Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?
Aug 24Is HUTCHMED (China) (LON:HCM) A Risky Investment?
May 10With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For
Apr 19Shareholder Returns
| HCM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.5% | -0.6% | -1.5% |
| 1Y | 33.8% | 8.7% | 3.8% |
Price Volatility
| HCM volatility | |
|---|---|
| HCM Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,988 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
HUTCHMED (China) Limited Fundamentals Summary
| HCM fundamental statistics | |
|---|---|
| Market cap | UK£2.50b |
| Earnings (TTM) | UK£79.42m |
| Revenue (TTM) | UK£660.35m |
31.5x
P/E Ratio3.8x
P/S RatioIs HCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCM income statement (TTM) | |
|---|---|
| Revenue | US$838.00m |
| Cost of Revenue | US$686.45m |
| Gross Profit | US$151.55m |
| Other Expenses | US$50.77m |
| Earnings | US$100.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 18.08% |
| Net Profit Margin | 12.03% |
| Debt/Equity Ratio | 10.7% |
How did HCM perform over the long term?
See historical performance and comparison